Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women

Bone

Volumn 30, Issue 4, 2002, Pages 599-603

  Neele, S J M ^a   Evertz, R ^a   De Valk De Roo, G ^a   Roos, J C ^a   Netelenbos, J C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Discontinuation; HRT; Osteoporosis treatment; SERMS

Indexed keywords

CONJUGATED ESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; FEMALE; FEMUR NECK; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

BONE DENSITY; ESTROGENS; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0036209190     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(01)00706-2     Document Type: Article

References (33)

1. Increased loss of trabecular but not cortical bone density, 1 year after discontinuation of 2 years hormone replacement therapy with Tibolone
2. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
3. Alendronate and estrogen effects in postmenopausal women with low bone mineral density
4. Long-term postmenopausal hormone replacement therapy effects on bone mass: Differences between surgical and spontaneous patients
5. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy
6. Raloxifene: A review of its use in postmenopausal osteoporosis
7. Estrogen and calcium supplement use among Japanese-American women: Effects upon bone loss when used singly and in combination
8. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
9. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women
10. Effects on bone mass after eight years of hormonal replacement therapy
11. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
12. Cyclical etidronate therapy for prevention of postmenopausal bone loss: A 1-year open-label follow-up study
13. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women
14. Effect on bone of withdrawal of oestrogen therapy
15. Effects of raloxifene (RLX), alendronate (ALN) and RLX + ALN on bone mineral density (BMD) and biochemical markers of bone turnover in postmenopausal women with osteoporosis
16. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: Three-year data from 2 double-blind, randomized, placebo-controlled trials
17. Cytokines, bone remodeling, and estrogen deficiency: A 1998 update
18. Bone response to termination of oestrogen treatment
19. Treatment of postmenopausal osteoporosis with transdermal estrogen
20. Fracture protection provided by long-term estrogen treatment
21. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment
22. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women
23. Alendronate in early postmenopausal women: Effects on bone mass during long-term treatment and after withdrawal
24. Overview of osteoporosis
25. Effect of hormonal replacement therapy withdrawal on bone mass and bone turnover: The Offely Study
26. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women
27. Bone turnover in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy
28. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: A prospective, randomized study
29. Skeletal benefits of alendronate: 7-Year treatment of postmenopausal osteoporotic women
30. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women
31. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis
32. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial
33. Mineral density gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinuance